Logo
x

Search category

Subscribe Now

P-III study

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis

  • July 16, 2021
GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

  • March 18, 2021
Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

  • March 10, 2021
Merck to Acquire OncoImmune for $425M

Merck to Acquire OncoImmune for $425M

  • November 24, 2020
Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six

Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six

  • October 1, 2020
Henlius Presents P-III Data of HLX04 (biosimilar- bevacizumab) at CSCO 2020

Henlius Presents P-III Data of HLX04 (biosimilar- bevacizumab) at CSCO 2020

  • September 20, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.